[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ckd-5d-hemodialysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ckd-5d-hemodialysis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,68,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100652618","real-world-efficacy-and-safety-of-tenapanor-plus-phosphate-binders-in-hemodialysis-patients-with-hyperphosphatemia-100652618",false,"NCT07776119","Real-World Efficacy and Safety of Tenapanor Plus Phosphate Binders in Hemodialysis Patients With Hyperphosphatemia","Inclusion Criteria:\n\n1. The subject has provided written informed consent prior to the initiation of any study-related activities.\n2. Male or female subjects aged ≥18 years at the time of signing the informed consent form.\n3. The subject is receiving regular maintenance hemodialysis (3 times per week, 4 hours per session) for at least 3 months.\n4. The patient has been on phosphate binder therapy for at least 3 weeks, with a stable dose.\n5. Serum phosphorus \\> 4.5 mg\u002FdL.\n\nExclusion Criteria:\n\n1. Hypersensitivity to Tenapanor or any excipients of the formulation.\n2. History of diarrhea within 1 week prior to the start of treatment. Diarrhea is defined as a Bristol Stool Form Scale (BSFS) score ≥6 (i.e., mushy or liquid stools with no solid pieces), a daily bowel movement frequency ≥3 times, and a duration of ≥2 days.\n3. Life expectancy \\\u003C 6 months.\n4. Expected or planned kidney transplantation during the study period.\n5. History of inflammatory bowel disease (IBD) or irritable bowel syndrome with diarrhea (IBS-D).\n6. Any other condition that, in the opinion of the Investigator, makes the patient unsuitable for enrollment.","ALL","18 Years","100 Years",{"count":19,"type":20},200,"ESTIMATED","6 Months","OBSERVATIONAL","The efficacy and safety of tenapanor plus PBs in Chinese patients are still unclear. Therefore, we aim to conduct a real-world study to explore the effect of combining two drugs with different mechanisms on hyperphosphatemia management.This real-world study will enroll hemodialysis patients with hyperphosphatemia who are on PBs therapy.",[25,26],"CKD 5D, Hemodialysis","Hyperphosphatemia Undergoing Hemodialysis","NOT_YET_RECRUITING","2026-08-17",{"date":30,"type":31},"2026-08-20","ACTUAL",{"date":30,"type":20},{"date":34,"type":20},"2027-10-10",{"name":36,"class":37},"Peking University People's Hospital","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100640735","personalized-two-stage-regional-citrate-anticoagulation-for-crrt-in-patients-with-citrate-metabolism-impairment-100640735","NCT07579663","Personalized Two-stage Regional Citrate Anticoagulation for CRRT in Patients With Citrate Metabolism Impairment","Personalized Two-stage Regional Citrate Anticoagulation for CRRT in Patients With Citrate Metabolism Impairment: a Multicenter Randomized Controlled Study","PRECISE","Inclusion Criteria:\n\nA. Aged 18 to 80 years, inclusive, male or female; B. Diagnosed with acute kidney injury or chronic kidney disease stage 5, and assessed by a physician as requiring continuous renal replacement therapy (CRRT); C. Citrate metabolism disorder, including liver failure (acute liver failure, acute-on-chronic liver failure, or decompensated cirrhosis), and\u002For microcirculation disorder (mean arterial pressure \\\u003C65 mmHg requiring vasopressor therapy and lactate ≥2 mmol\u002FL); D. The investigator determines that the patient can have a stable vascular access established (the access must be capable of providing a constant and effective blood flow rate \\>150 ml\u002Fmin); E. The study participant (subject) and their legal guardian are able to understand the study purpose and provide written informed consent.\n\nExclusion Criteria:\n\nA. Received regional citrate anticoagulation therapy within the previous 72 hours; B. Expected to require additional non-protocol calcium supplementation during CRRT due to disease-related needs; C. Requiring arterial-venous reversal of the extracorporeal circuit during CRRT due to poor flow; D. Requiring concurrent peritoneal dialysis during the trial period; E. Participated in or is currently participating in another clinical trial within 1 month prior to the date of signing the informed consent form; F. Expected survival time less than 72 hours; G. Any other conditions that, in the investigator's judgment, make the patient unsuitable for participation in the clinical trial.","80 Years",{"count":49,"type":20},142,"INTERVENTIONAL",[52],"NA","The purpose of this study is to compare the efficacy and safety of an individualized two-stage calcium supplementation method versus a conventional commercial RCA-CRRT module in RCA-CRRT for patients with citrate metabolism disorders.",[55,25,56],"AKI - Acute Kidney Injury","Hepatic Failure",[58,59],"Regional Citrate Anticoagulation (RCA)","Continuous Renal Replacement Therapy (CRRT)","2026-05-05",{"date":62,"type":31},"2026-05-12",{"date":60,"type":20},{"date":65,"type":20},"2028-08-14",{"name":67,"class":37},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":50,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100633410","difelikefalin-for-itching-in-hemodialysis-patients-with-chronic-kidney-disease-100633410","NCT07526324","Difelikefalin for Itching in Hemodialysis Patients With Chronic Kidney Disease","Effect of Difelikefalin on CKD-Associated Pruritus in Patients on Maintenance Hemodialysis: A Randomized, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Adult patients aged ≥18 years\n* Diagnosed with chronic kidney disease (CKD) on maintenance hemodialysis Undergoing hemodialysis for at least 3 months\n* Presence of moderate-to-severe pruritus defined as Worst Itching Intensity Numerical Rating Scale (WI-NRS) score ≥4\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Known case of Primary skin disesease associated with Itching.\n* Known case of liver disease.\n* Known case of iron defeciency anaemia ,hematological malignancy.\n* Known case of hypothyroidism \\& hyperthyroidism.\n* Known case of allergic reaction to Opiates .\n* Pregnancy.\n* Drug abuse, or substance dependence",{"count":76,"type":20},106,[52],"A randomized, placebo-controlled, double-blind trial will be conducted in the Department of Nephrology at Chittagong Medical College Hospital, Chattogram, Bangladesh, over a period of one and a half years. A total of 102 patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis will be enrolled in the study.\n\nPatients with moderate-to-severe pruritus, defined as a Worst Itching Intensity Numerical Rating Scale (WI-NRS) score ≥ 4, will be included. Eligible participants will be randomly assigned in a 1:1 ratio to receive either difelikefalin (0.5 mcg\u002Fkg) or placebo administered intravenously after each hemodialysis session for 6 weeks.\n\nThe primary outcome measure will be the change in WI-NRS score from baseline to week 6. Secondary outcomes will include changes in quality of life assessed using the Skindex-10 scale. Adverse events and safety parameters will also be monitored throughout the study period.\n\nThe primary analysis will be conducted using the intention-to-treat principle. A per-protocol analysis may also be performed as a secondary analysis. Statistical analysis will be carried out using SPSS version 27.",[80,25],"Itching Symptoms","2026-04-10",{"date":83,"type":31},"2026-04-13",{"date":85,"type":20},"2026-04-26",{"date":87,"type":20},"2027-01-30",{"name":89,"class":37},"Chittagong Medical College",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":50,"phases":99,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":38},"100585784","phase-2-activated-charcoal-use-in-chronic-kidney-disease-patients-100585784","NCT06906874","Activated Charcoal Use in Chronic Kidney Disease Patients","Efficacy and Safety of Activated Charcoal on Mineral Bone Disorder in Chronic Kidney Disease Patients","Inclusion Criteria:\n\n1. Adult aged ≥18 years with ESRD.\n2. Patients who had been on stable maintenance hemodialysis (3 times weekly) for at least 6 months.\n3. Patients receiving phosphate binders according to standard protocols established by kidney disease: Improving Global Outcomes (KDIGO).\n\nExclusion Criteria:\n\n1. Severely malnourished (as diagnosed by the department's dietitian).\n2. Treated with overnight dialysis.\n3. Primary hyperparathyroidism or persistent serum levels of intact parathyroid hormone greater than 800 pg\u002FmL.",{"count":98,"type":20},40,[100],"PHASE2","Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.",[103,25,104],"End Stage Renal Disease (ESRD)","CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder","RECRUITING","2025-08-05",{"date":108,"type":31},"2025-08-08",{"date":110,"type":20},"2025-08",{"date":112,"type":20},"2025-11",{"name":114,"class":37},"Mansoura University"]